Purpose: COViK, a prospective hospital-based multicenter case-control study in Germany, aims to assess the effectiveness of COVID-19 vaccines against severe disease. Here, we report vaccine effectiveness (VE) against COVID-19-caused hospitalization and intensive care treatment during the Omicron wave. Methods: We analyzed data from 276 cases with COVID-19 and 494 control patients recruited in 13 hospitals from 1 December 2021 to 5 September 2022. We calculated crude and confounder-adjusted VE estimates. Results: 21% of cases (57/276) were not vaccinated, compared to 5% of controls (26/494; p < 0.001). Confounder-adjusted VE against COVID-19-caused hospitalization was 55.4% (95% CI: 12–78%), 81.5% (95% CI: 68–90%) and 95.6% (95%CI: 88–99%) after two, three and four vaccine doses, respectively. VE against hospitalization due to COVID-19 remained stable up to one year after three vaccine doses. Conclusion: Three vaccine doses remained highly effective in preventing severe disease and this protection was sustained; a fourth dose further increased protection.
The front cover picture confronts the two different states of a visible-light photoswitchable peptide in complex with the WDR5 protein. The green background represents the 520 nm irradiation, which leads the cis isomer, whereas the blue one illustrates the 405 nm irradiation for the trans isomer. In our paper, we describe two novel peptide backbone photoswitches capable of disrupting epigenetic protein–protein interactions differently upon visible-light illumination. We believe that these building blocks will find applications beyond protein control. More information can be found in the full paper by O. Vázquez et al. on page 1417 in Issue 11, 2019 (DOI: 10.1002/cbic.201800737).